Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2021

View Archived Issues

CEPI and VBI Vaccines partner to develop eVLP vaccine candidates against COVID-19 variants

Venatorx selects VNRX-9945 as clinical candidate against HBV

Enrollment opens in phase III trial of [177Lu]PNT-2002 for metastatic CRPC

First clinical results reported for SeVRSV vaccine in healthy adults

Moderna begins dosing with modified COVID-19 vaccines in amended phase II study

Nouscom cleared in Spain to begin phase Ib study of personalized cancer immunotherapy NOUS-PEV

First patients enrolled in phase I study of PTP-001 as treatment of knee OA

Positive biomarker data from phase II study of EB-613 in postmenopausal osteoporosis

Renibus initiates phase II trial of RBT-1 for prevention of AKI

BeiGene discloses MAP4K1 inhibitors

Sichuan Haisco Pharmaceutical synthesizes influenza virus hemagglutinin inhibitors

Hinova Pharmaceuticals identifies new thyroid hormone receptor beta agonists

Genfleet Therapeutics presents GTPase KRAS mutant inhibitors

BoYuan RunSheng Pharma patents CAR T cells for cancer

Novel antibody cocktail prevents SARS-CoV-2 viral escape mutations

Direct bladder vaccination halts recurrent UTIs

Tilavonemab does not show evidence of efficacy in phase II study in progressive supranuclear palsy

Sanofi and Translate Bio begin phase I/II study of MRT-5500 mRNA COVID-19 vaccine candidate

Takeda compound targets O-GlcNAcase for neurodegenerative disorders

SymBio submits IND for phase II trial of intravenous brincidofovir for pediatric AdV infections

Brilacidin inhibits SARS-CoV-2 in vitro

European Commission grants conditional marketing authorization for J&J COVID-19 vaccine

VX-880 enters phase I/II trial for type 1 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...